Lineage Cell Therapeutics Inc (NYSE MKT:LCTX) — Market Cap & Net Worth
Market Cap & Net Worth: Lineage Cell Therapeutics Inc (LCTX)
Lineage Cell Therapeutics Inc (NYSE MKT:LCTX) has a market capitalization of $352.40 Million ($352.40 Million) as of May 3, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #14309 globally and #3232 in its home market, demonstrating a -1.92% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lineage Cell Therapeutics Inc's stock price $1.53 by its total outstanding shares 230327537 (230.33 Million). Analyse LCTX operating cash flow to see how efficiently the company converts income to cash.
Lineage Cell Therapeutics Inc Market Cap History: 2015 to 2026
Lineage Cell Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $810.36 Million to $352.40 Million (-7.45% CAGR).
Lineage Cell Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lineage Cell Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
12.18x
Lineage Cell Therapeutics Inc's market cap is 12.18 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $810.36 Million | $2.53 Million | -$46.99 Million | 319.80x | N/A |
| 2016 | $772.38 Million | $2.25 Million | $33.57 Million | 342.98x | 23.01x |
| 2017 | $460.01 Million | $1.79 Million | -$19.98 Million | 256.70x | N/A |
| 2018 | $210.29 Million | $1.42 Million | -$45.99 Million | 148.51x | N/A |
| 2019 | $204.99 Million | $1.48 Million | -$11.71 Million | 138.70x | N/A |
| 2020 | $405.38 Million | $773.00K | -$20.65 Million | 524.42x | N/A |
| 2021 | $564.30 Million | $3.90 Million | -$43.02 Million | 144.84x | N/A |
| 2022 | $269.48 Million | $14.70 Million | -$26.27 Million | 18.33x | N/A |
| 2023 | $251.06 Million | $8.95 Million | -$21.49 Million | 28.07x | N/A |
| 2024 | $115.74 Million | $9.50 Million | -$18.61 Million | 12.18x | N/A |
Competitor Companies of LCTX by Market Capitalization
Companies near Lineage Cell Therapeutics Inc in the global market cap rankings as of May 3, 2026.
Key companies related to Lineage Cell Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Lineage Cell Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Lineage Cell Therapeutics Inc's market cap moved from $810.36 Million to $ 352.40 Million, with a yearly change of -7.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $352.40 Million | -8.38% |
| 2025 | $384.65 Million | +232.34% |
| 2024 | $115.74 Million | -53.90% |
| 2023 | $251.06 Million | -6.84% |
| 2022 | $269.48 Million | -52.24% |
| 2021 | $564.30 Million | +39.20% |
| 2020 | $405.38 Million | +97.75% |
| 2019 | $204.99 Million | -2.52% |
| 2018 | $210.29 Million | -54.29% |
| 2017 | $460.01 Million | -40.44% |
| 2016 | $772.38 Million | -4.69% |
| 2015 | $810.36 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Lineage Cell Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $352.40 Million USD |
| MoneyControl | $352.40 Million USD |
| MarketWatch | $352.40 Million USD |
| marketcap.company | $352.40 Million USD |
| Reuters | $352.40 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic… Read more